| September 14, 2026 | Regulated Bioanalysis Workshop | |
| September 15, 2026 | Discovery Bioanalysis and New Technologies Workshop | |
| September 16, 2026 | Mechanistic ADME Workshop |
********DOWNLOAD APA 2026 CONFERENCE PROGRAM ********
Regulated Bioanalysis Workshop - Monday, September 14, 2026
|
Title |
Speaker |
Company |
Time |
|
Registration, Breakfast, Exhibits |
|
7:30 - 8:30 |
|
|
Workshop Introduction. |
Jeongsup Shim |
Genentech |
8:30 - 8:40 |
|
Session I: Regulatory & Agency Perspectives |
|||
|
Session Introduction: Ryan Lo, Moderna; Aihua Liu, Resolian; Nevena Mollova, Gilead & Ying Zhang, BA Consulting |
|
|
8:40 - 8:45 |
|
Oversight of Bioavailability and Bioequivalence Studies in Support of New and Generic Drugs and Therapeutic Biologics |
Sean Kassim |
FDA |
8:45 - 9:05 |
|
Evaluating Partial Bioanalytical Method Validations in ANDAs Under ICH M10 Guidance |
Yang Lu |
FDA |
9:05 - 9:25 |
|
Common Biomarker Challenges Encountered in Clinical Development |
Heather Myler |
Takeda |
9:25 - 9:45 |
|
Plenary Talk: Challenges and Opportunities in Biomarker Bioanalysis |
Chongwoo Yu |
FDA |
9:45 - 10:20 |
|
Panel Discussion: Sean Kassim, FDA; Yang Lu, FDA; Heather Myler, Takeda; Chongwoo Yu, FDA; Sarah Bean, Charles River Laboratories |
|
|
10:20 - 10:40 |
|
AM Break & Exhibits |
|
|
10:40 - 11:10 |
|
Sponsor Presentation: Introducing the Novus V55 System: Re-envisioning LC-MS Bioanalysis Combining Quantitative Felexibility With Reliable Performance |
Matthew Stone |
|
11:10- 11:20 |
|
Session II: Emerging Technologies in BA & Next Gen. Modalities |
|||
|
Session Introduction: Yongjun Xue, BMS; Darshana Jani, Moderna; Seema Kumar, Flagship & Jeongsup Shim, Genentech |
|
|
11:20 - 11:25 |
|
Emerging Hybrid LC-HRMS Assays for In Vivo DAR Shift Bioanalysis of ADCs |
Joshua Powers |
BMS |
11:25 - 11:50 |
|
Application of NULISA for Broad-Range Pharmacokinetic and Low-Volume Biomarker Analysis |
Jeongsup Shim |
Genentech |
11:50 - 12:15 |
|
Bioanalytical and Translational Considerations for Therapeutic siRNA and ASOs: Industry Practices and IQ Consortium Recommendations |
Guangnong (Sunny) Zhang |
Novo Nordisk |
12:15 - 12:40 |
|
Lunch, Exhibits, and Poster Viewing (1:10- 2:00 PM) |
|
12:40 - 2:00 |
|
|
Rapid-Fire Poster Presentations Moderator: Brendan Tierney, Pfizer 1. Richard Dambra, Boehringer Ingelheim -Development and Validation of A Clinical nAb Assay For A Replicating Oncolytic Virus 2. Andy (Hongfang) Xue, Resolian - A Novel LC-MS/MS Strategy for Quantification of TGW101 Conjugated Payload in Human Plasma via Chemically Controlled Release of a Click-to-Release ADC Linker |
|
|
2:00 - 2:10 |
|
Session III: Immunogenicity & ADA in Regulated Context |
|||
|
Session Introduction: Jennifer Cunliffe, Novartis; Fumin Li, Unitides Bioanalytical Lab & James Schiller, Merck |
|
2:10 - 2:15 |
|
|
Insights into Immunogenicity Testing of Contemporary Peptide Therapeutics |
Ron Bowsher |
B2S Labs |
2:15 - 2:40 |
|
Use of NAM-based Preclinical Risk Assessment Tools to Support a Streamlined Immunogenicity Strategy in Clinc for Biologics |
Vibha Jawa |
EpiVax,Inc. |
2:40 - 3:05 |
|
Implementing Streamlined Immunogenicity Assessment: From Analysis to Submission |
Jenny Valentine |
Regeneron |
3:05 - 3:30 |
|
PM Break & Exhibits |
|
|
3:30 - 4:00 |
|
Session IV: AI/ML in Regulated Bioanalysis |
|||
|
Session Introduction: Niketa Jani, Novartis; Ang Liu, Johnson and Johnson & Erik Burns, Alturas Analytics |
|
|
4:00 - 4:05 |
|
Augmenting Science and Strengthening Quality: AI Driven Transformation in Regulated Bioanalysis |
Michelle Groff |
Johnson & Johnson |
4:05 - 4:30 |
|
Enabling the AI-Ready Bioanalytical Lab: Adoption, Governance, and Scale |
Jason DelCarpini |
Moderna |
4:30 - 4:55 |
|
Artificial Intelligence in Regulated Science: Defining the Standards Before They Define Us |
Jera Kantz & Sara Underwood |
Alturas Analytics |
4:55 - 5:20 |
|
Workshp Closing Comments & Raffle |
Jinsong Yang |
Keros Therpeutics |
5:20 - 5:25 |
|
Reception & Sciex's Mixer Event - Shane Needham, Veloxity Labs
|
 |
5:25 - 6:40 | |
Discovery Bioanalysis and New Technologies Workshop - Tuesday, September 15, 2026
|
Title |
Speaker |
Company |
Time |
|
Registration, Breakfast, Exhibits |
|
7:30 - 8:30 |
|
|
Workshop Introduction |
Paddy Eangoor |
Sanofi |
8:30 - 8:35 |
|
Session I: Bioanalytical Approaches and Strategies for Therapeutic and Conjugated Oligonucleotides |
|||
|
Session Introduction: Ju Liu, Eli Lilly; Linlin Dong, Takeda & Hongying Gao, Innovo Bioanalysis |
|
|
8:35 - 8:40 |
|
qPCR-Based Quantification of siRNA Therapeutics in Plasma and Tissues: Bioanalytical Considerations for Pharmacokinetic and Biodistribution Studies |
Irina Laczkovich |
Takeda |
8:40 - 9:05 |
|
Overview of Hybridization ELISA for Oligonucleotide Quantitation |
Sarah Dicker |
Eli Lilly |
9:05 - 9:30 |
|
Quantitative Bioanalysis of Antibody-Oligonucleotide Conjugates: Challenges, Strategies, and Emerging Solutions |
Long Yuan |
Biogen |
9:30 - 9:55 |
|
Beyond GalNAc-siRNA: Bioanalytical Strategy for bispecific siRNA, Aptamer-Drug Conjugate and ADA |
Min Meng |
Resolian |
9:55 - 10:20 |
|
Sponsor Presentation: Sample Collection Procedures and Potential Impacts to Bioanalysis |
Jason Hamilton |
|
10:20 - 10:30 |
|
AM Break & Exhibits |
|
10:30 - 11:00 |
|
|
Session II: Bioanalysis Hot Topics |
|||
|
Session Introduction: Paddy Eangoor, Sanofi & Jonathan Joseph, Takeda |
|
|
11:00 - 11:05 |
|
Rapid Fire Poster Presentations 1. Xien Yu Chua, Alnylam - Observation of a Single-Stranded Lipophilic siRNA Metabolite in Plasma 2. Yipei Zhang, Takeda - A Nove Immunoaffinity Nano-LC/MS Workflow to Assess Linker Integrity and In Vivo Activation of a Complex Conditional Bispecific T Cell Engager 3. Xiaodong Zhu, Worldwide Clinical Trials - Development of Highly Sensitive and Robust LC-MS/MS Methods for Protein and Peptide Therapeutics 4. Dennis Van De Goor, Sanofi - AI-Assisted Development of a Bi-active Ligand Binding Assay for Pharmacokinetic Assessment of Monoclonal Antibodies 5. Kristina Shqillo, Novartis - Advancing Platform-Based Bioanalytical Assay Development Across Drug Programs and Endpoints Through Shared Generic Antibody Tools |
|
11:05 - 11:30 |
|
|
Digital or Quantitative? Choosing the right PCR Platform for Bioanalytical Applications |
Amanda Hayes |
Bioagilytix |
11:30 - 11:55 |
|
Implementing a generic ADA assay strategy to measure free and complexed ADA that can efficiently address TK and safety‑related ADA considerations in a preclinical setting |
Rodd Polsky |
GSK |
11:55 - 12:20 |
|
Rapid-Fire Poster Presentations 1. Yinzheng Guan, Sanofi - Optimizing Hybridization Probe Selection for Intact and Total ASO Quantification by LBA in Antisense Oligonucleotide Conjugated Bioanalysis 2. David Zuluaga-Rave, Resolian - A Novel Immunocapture Nano-LC-MS/MS Platform for Ultra-Sensitive Quantitation of STAT6 as a Translational Biomarker for RNa-Degrading Therapeutics in Human Tissues 3. Shamael Dastagir, Sanofi - NULISA qPCR Custom Singleplex Method Development for Pharmacokinetic/Pharmacodynamic Assessment 4. Mark Wissel, Eurofins - Supporting Shedding, Biodistribution and Infection Identification Bioanalysis: The Optimization of Methods for Urine in Bioanalytical qPCR 5. Prakash Bhosale, IQVIA - Cross-Platform ADC Bioanalysis: Harmonized LBA, Hybrid IA-LCMS, and LC-MS Strategies |
|
|
12:20 - 12:45 |
|
Lunch, Exhibits, and Poster Viewing (1:20 - 2:00 pm) |
|
12:45 - 2:00 |
|
|
Sponsor Presentation: SMab™ Technology for Bioanalytical Critical Reagent Discovery |
Hao Cheng |
|
2:00 - 2:10 |
|
Session III: Biomarkers & Multi-Omics in Discovery |
|||
|
Session Introduction: Catherine Vrentas, Alnylam & Yu Tian, AbbVie |
|
|
2:10 - 2:15 |
|
Leveraging Multidimensional Spatial-Omics Tools To Empower Our Understanding of Disease Pathobiology and Target Validation in the Industry Setting |
Silva Siso |
AbbVie |
2:15 - 2:40 |
|
Integrating Advanced Cell Models, Multiomics, and AI for Safety Prediction |
Jurre Kamphorst |
AstraZeneca |
2:40 - 3:05 |
|
From Spatial Biomarkers to Development Decisions: Practical Applications Across Preclinical and Clinical Drug Development |
Corinne Ramos |
Aliri |
3:05 - 3:30 |
|
PM Break and Exhibits |
|
3:30 - 3:55 |
|
|
Session IV: Case Studies on Novel Technologies & Implementation |
|||
|
Session Introduction: Zachary Parsons, BMS & Maria Myzithras, Boehringer-Ingelheim |
|
3:55 - 4:00 |
|
|
Plenary Talk: Harnessing AI for Bridging Translational Gaps in Drug Discovery |
Lei Xie |
Northeastern Univeristy |
4:00 - 4:40 |
|
Ex vivo Biotransformations Masquerading as Bioanalytical Method Anomalies |
Zach Parsons |
BMS |
4:40 - 5:05 |
|
Networking Reception and Exhibits |
|
5:05 - 6:20 |
|
Mechanistic ADME Workshop - Wednesday, September 16, 2026
|
Title |
Speaker |
Company |
Time |
|
Registration, Breakfast, Exhibits |
|
7:30 - 8:30 |
|
|
Workshop Introduction |
Nagendra Chemuturi |
Eli Lilly |
8:30 - 8:40 |
|
Plenary Talk - Applications of Complex in vitro Models of the Kidney and Intestine in Modeling Drug Disposition |
Edward Kelly |
University of Washington |
8:40 - 9:20 |
|
Session I: New Approach Methodologies for Drug Metabolism & Toxicity |
|||
|
Session Introduction: Raman Sharma, Pfizer; Chandra Prakash, CP Pharma Solutions & David Stresser, AbbVie |
9:20 - 9:25 |
||
|
Pharmaceutical Industry Perspective on Opportunities and Considerations for NAMs in Drug Discovery |
Patrick Devine |
BMS |
9:25 - 9:50 |
|
Human Organ Chips in Toxicology: From Model Establishment to Validation |
Haiqing Bai |
Xellar Bio |
9:50 - 10:15 |
|
Mind the Gap: In Silico ADME as a New Approach Methodology for Human Prediction |
Michael McCoy |
Takeda |
10:15 - 10:40 |
|
AM Break & Exhibits |
|
|
10:40 - 11:10 |
|
Sponsor Presentation: Detection to Decision: High-Throughput Small-Molecule DMPK on the 6495D - and When High Resolution Belongs in the ADME Lab |
Christopher Colangelo |
|
11:10 - 11:25 |
|
Session II: Metabolism, Metabolites & Alternate Models - Mechanistic Insights into Drug Metabolism, Human Metabolites, and Predictive Models |
|||
|
Session Introduction: Eric Ballard, Takeda & James Driscoll, Kardigan Bio |
|
11:25 - 11:30 |
|
|
A Comparison of In Vitro and In Vivo Metabolite Profiles: How Quantitatively Predictive are Our In Vitro Assays? |
Matt Cerny |
Pfizer |
11:30 - 11:55 |
|
In Vitro-In Vivo Extrapolation Inaccuracy: The CYP3A4 Anomaly In Vitro and Utilizing PBPK Modeling to Understand CYP3A4/P-gp Interplay |
Christine Bowman |
Genentech |
11:55 - 12:20 |
|
Combining MetID, Quantitative Enzymology, and In Vitro Ames to Profile the Potential Bioactivation and Genotoxicity Risks for N-nitroso Paroxetine |
Carley Heck |
Pfizer |
12:20 - 12:45 |
|
Lunch, Exhibits, and Poster Viewing (1:05 - 1:45 pm) |
|
12:45 - 1:45 |
|
|
Rapid-Fire Poster Presentations Moderator: Christopher Kochansky, Exelixis 1. Jaimie Townsend, Novartis - Advancing Human-Relevant Prediction of Complex CYP3A4 DDIs: Insights From 8HUM Mice and Microfluidic Liver-On-Chip Technologies 2. Kari Martyniak, Pfizer - Comparative Temporal Proteomic Profiling of Primary Hepatocytes Cultures From Preclinical Species and Humans |
1:45 - 1:55 | ||
|
Session III: Mechanistic ADME of Beyond the Rule of 5 (BRo5) Molecules |
|||
|
Session Introduction: Christopher Kochansky, Exelixis; Nagendra Chemuturi, Lilly & April Chen, AstraZeneca |
|
|
1:55 - 2:00 |
|
Beyond Rule-of-5: ADME Challenges and Opportunities for Oral and CNS-Active Targeted Protein Degraders |
Ritu Singh |
C4 Therapeutics |
2:00 - 2:25 |
|
Allometric Scaling as a Viable and Practical Approach for Peptide PK Prediction |
Ryota Kikuchi |
AbbVie |
2:25 - 3:00 |
|
PM Break & Exhibits |
|
|
3:00 - 3:20 |
|
ADME and PKPD Consideration in the Discovery of RAS(ON) Tri-complex Inhibitors: Daraxonrasib and Elironrasib as Examples |
Zhican Wang |
Revolution Medicine |
3:20 - 3:45 |
|
Session IV: PK/PD Strategies From Preclinical Discovery to Human Dose Projection |
|||
|
Session Introduction: Sara Shum, City Therapeutics, Donglu Zhang, Genentech; & Hongbin Yu, Boehringer-Ingelheim |
|
|
3:45 - 3:50 |
|
Preclinical PK/PD: Translational Considerations for Human Dose Prediction in Drug Discovery |
Niklas Kroemer |
Boehringer-Ingelheim, Germany |
3:50 - 4:15 |
|
Driving Targeted Protein Degrader Discovery Through Quantitative PK/PD Modeling |
Valerie Kramlinger |
Amgen |
4:15 - 4:40 |
|
Conference Closing Remarks |
|
4:40- 4:45 |
|